Abstract
Recently, polymorphisms in macrophage inhibitory cytokine-1 ( MIC1 ) and interleukin 1 receptor antagonist ( IL1RN ) were identified to be associated with prostate cancer risk ([1][1]-[3][2]). MIC-1 is a divergent member of the transforming growth factor-β superfamily of cytokines. In the Cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
